GlaxoSmithKline PLC: GSK amends emerging market da | Company Announcements

Thursday 04 February, 2010

GlaxoSmithKline PLC

GSK amends emerging market da

RNS Number : 7154G

GlaxoSmithKline PLC

04 February 2010

GSK amends emerging market data in 2009 year end unaudited results

GSK's unaudited preliminary results announcement for the year ended 31st December 2009 issued at 12:00 GMT 4^th February 2010 (RNS No 6871G) included the following sentence "If we use the broader definition of 'emerging markets'^# , GSK sales grew 28% and represented 24% of turnover".

This sentence should read: "If we use the broader definition of 'emerging markets'^# , GSK sales grew 16% and represented 21% of turnover".

#Includes Pharmaceutical and Consumer Healthcare sales in GSK's Emerging Markets region plus Central and Eastern Europe and Asia Pacific markets (excluding Japan, Australia and New Zealand).

This has now been updated to show the correct numbers. All other information within the announcement remains unchanged.

SM Bicknell

Company Secretary

4^th February 2010

This information is provided by RNS

The company news service from the London Stock Exchange

END

MSCBLGDDXDGBGGS

Investegate takes no responsibility for the accuracy of the information within the site.

The announcements are supplied by the denoted source. Queries about the content of an announcement should be directed to the source. Investegate reserves the right to publish a filtered set of announcements. NAV, EMM/EPT, Rule 8 and FRN Variable Rate Fix announcements are filitered from this site.